Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca
Pinetree Therapeutics has entered into an exclusive option and global license agreement with AstraZeneca for a preclinical EGFR degrader candidate. The deal includes:
- Up to $45 million in upfront and near-term payments
- Total deal value of over $500 million, including potential milestone payments
- Tiered royalties on net sales worldwide
Pinetree's pan-EGFR degrader, developed from their proprietary AbReptor™ multispecific antibody platform, has shown promising preclinical anti-tumor activity in drug- and TKI-resistant tumors. The agreement allows AstraZeneca to exclusively license the candidate for global development and commercialization.
Pinetree Therapeutics ha stipulato un accordo di opzione esclusiva e di licenza globale con AstraZeneca per un candidato degrader EGFR in fase preclinica. L'accordo comprende:
- Fino a 45 milioni di dollari in pagamenti anticipati e a breve termine
- Un valore totale dell'accordo superiore ai 500 milioni di dollari, inclusi potenziali pagamenti per traguardi
- Royalty scaglionate sulle vendite nette a livello mondiale
Il degrader pan-EGFR di Pinetree, sviluppato dalla loro piattaforma di anticorpi multispecifici proprietaria AbReptor™, ha mostrato un'attività anti-tumorale preclinica promettente in tumori resistenti a farmaci e TKI. L'accordo consente ad AstraZeneca di licenziare esclusivamente il candidato per lo sviluppo e la commercializzazione globali.
Pinetree Therapeutics ha firmado un acuerdo de opción exclusiva y licencia global con AstraZeneca para un candidato degrader EGFR en fase preclínica. El acuerdo incluye:
- Hasta 45 millones de dólares en pagos iniciales y a corto plazo
- Un valor total del acuerdo de más de 500 millones de dólares, incluidos posibles pagos de hitos
- Regalías escalonadas sobre las ventas netas a nivel mundial
El degrader pan-EGFR de Pinetree, desarrollado a partir de su plataforma de anticuerpos multispecíficos AbReptor™, ha mostrado una prometedora actividad antitumoral preclínica en tumores resistentes a fármacos y TKI. El acuerdo permite a AstraZeneca licenciar exclusivamente el candidato para su desarrollo y comercialización global.
Pinetree Therapeutics는 AstraZeneca와 EGFR 분해 후보 물질에 대한 독점 옵션 및 글로벌 라이센스 계약을 체결했습니다. 이 계약에는 다음이 포함됩니다:
- 최대 4,500만 달러의 선불 및 단기 지불
- 잠재적 마일스톤 지불을 포함하여 총 계약 가치가 5억 달러를 초과하는 것
- 전 세계 순매출에 대한 단계별 로열티
Pinetree의 범-EGFR 분해자는 그들의 독창적인 AbReptor™ 다중 특이성 항체 플랫폼에서 개발되었으며, 약물 및 TKI 저항성 종양에서 유망한 전임상 항종양 활성을 보여주었습니다. 이 계약을 통해 AstraZeneca는 후보 물질을 전 세계적으로 개발 및 상업화하는 독점 라이센스를 가질 수 있습니다.
Pinetree Therapeutics a conclu un accord d'option exclusive et de licence mondiale avec AstraZeneca pour un candidat degrader EGFR en phase préclinique. L'accord comprend :
- Jusqu'à 45 millions de dollars en paiements initiaux et à court terme
- Une valeur totale de l'accord supérieure à 500 millions de dollars, y compris les paiements de jalons potentiels
- Des redevances échelonnées sur les ventes nettes dans le monde entier
Le degrader pan-EGFR de Pinetree, développé à partir de leur plateforme d'anticorps multispecifiques AbReptor™, a montré une activité antitumorale préclinique prometteuse dans des tumeurs résistantes aux médicaments et aux TKI. L'accord permet à AstraZeneca de licencier exclusivement le candidat pour le développement et la commercialisation à l'échelle mondiale.
Pinetree Therapeutics hat einen exklusiven Options- und globalen Lizenzvertrag mit AstraZeneca für einen präklinischen EGFR-Degrader-Kandidaten abgeschlossen. Das Geschäft umfasst:
- Bis zu 45 Millionen Dollar an Voraus- und kurzfristigen Zahlungen
- Ein Gesamtwert des Geschäfts von über 500 Millionen Dollar, einschließlich potenzieller Meilensteinzahlungen
- Gestaffelte Lizenzgebühren auf den Nettoumsatz weltweit
Der pan-EGFR-Degrader von Pinetree, entwickelt auf Basis ihrer proprietären AbReptor™-multispezifischen Antikörperplattform, hat vielversprechende präklinische anti-tumorale Aktivitäten bei medikamenten- und TKI-resistenten Tumoren gezeigt. Der Vertrag ermöglicht AstraZeneca die exklusive Lizenzierung des Kandidaten für die globale Entwicklung und Vermarktung.
- Potential for up to $45 million in upfront and near-term payments
- Total deal value exceeding $500 million including milestone payments
- Tiered royalties on net sales worldwide
- Promising preclinical anti-tumor activity in drug- and TKI-resistant tumors
- Enhanced activity when used in combination with current EGFR inhibitors
- None.
The agreement between Pinetree Therapeutics and AstraZeneca is significant for several financial reasons. First, the upfront and near-term payments of up to $45 million offer immediate liquidity to Pinetree, enhancing its financial stability and enabling further R&D investments. The total deal value of over $500 million, including potential milestone payments, signals a substantial infusion of capital contingent on the successful progression of the EGFR degrader candidate through various stages of development. This structured deal reduces financial risk for Pinetree while maintaining potential high rewards. Additionally, tiered royalties on net sales worldwide provide a continuous revenue stream if the product reaches commercial success. For investors, this signifies a well-structured financial deal that balances immediate gains with long-term revenue potential, significantly enhancing Pinetree's valuation and market attractiveness.
The focus on targeted protein degradation, particularly an EGFR degrader, is highly relevant in the oncology field. EGFR (Epidermal Growth Factor Receptor) plays a important role in the proliferation of cancer cells and its mutations are associated with various cancers, including lung and colorectal cancers. Pinetree's pan-EGFR degrader developed from the AbReptor™ platform has shown promising preclinical anti-tumor activity, especially in drug- and TKI-resistant tumors. This is a notable advancement as resistance to existing EGFR inhibitors is a significant challenge in oncology. The collaboration with AstraZeneca, a leader in oncology, not only validates the scientific potential of Pinetree's candidate but also expedites its clinical development. Investors should be optimistic about the strategic fit and potential breakthrough in addressing unmet medical needs in cancer treatment.
From a market perspective, this agreement strategically positions Pinetree in the competitive landscape of oncology therapeutics. Partnering with AstraZeneca, which has a strong global presence and extensive experience in oncology, enhances the likelihood of successful market entry and adoption of the EGFR degrader candidate. The deal also boosts Pinetree's credibility and can attract further partnerships or investments. Given the high market demand for effective cancer treatments, especially those overcoming resistance mechanisms, the commercial potential is significant. Furthermore, the option and license agreement structure allows AstraZeneca to de-risk its investment until the candidate shows more definitive results, which is a prudent market strategy. For retail investors, this deal signals strong future growth prospects and validates the innovative potential of Pinetree's technology.
Pinetree to receive up to
Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license Pinetree's preclinical EGFR degrader for global development and commercialization. In exchange, Pinetree will receive upfront and near-term payments of up to
"We are excited to announce this option and license agreement with AstraZeneca, a leading global biopharmaceutical company, to advance one of our novel receptor degrader programs into the clinic," said Dr. Hojuhn Song, Founder and CEO of Pinetree. "Pinetree's pan-EGFR degrader was developed from AbReptor™, our proprietary multispecific antibody platform and has demonstrated promising preclinical anti-tumor activity in drug- and TKI-resistant tumors as well as enhanced activity when used in combination with current EGFR inhibitors."
"Targeted protein degradation is a promising therapeutic modality. We are pleased to enter into this agreement with Pinetree, for an exclusive option to license its pan-EGFR degrader for investigation in EGFR expressing tumors, including those with EGFR mutations" said Puja Sapra, Senior Vice President, Oncology Targeted Discovery, Oncology R&D, AstraZeneca.
Pinetree is also advancing multiple preclinical candidates derived from its AbReptor™ TPD platform with potential in oncology and other therapeutics areas.
About Pinetree Therapeutics, Inc.
Established to combat drug resistance in oncology and beyond, Pinetree's platform technology, AbReptor™, is a best-in-class, transformative and modular antibody platform designed to degrade membrane-bound and extracellular proteins. Since its founding in 2019, Pinetree's platform has brought about several compelling pre-clinical programs in oncology and other therapeutic areas.
Please visit the Company's website at pinetreetx.com and connect on LinkedIn for more information.
Contact:
Clemens Reinshagen
admin@pinetreetherapeutics.com
Pinetree Therapeutics, Inc
+1-617-945-2309
View original content to download multimedia:https://www.prnewswire.com/news-releases/pinetree-therapeutics-announces-exclusive-option-and-global-license-agreement-for-preclinical-egfr-degrader-candidate-with-astrazeneca-302204218.html
SOURCE PineTree Therapeutics
FAQ
What is the value of Pinetree Therapeutics' deal with AstraZeneca (AZN) for the EGFR degrader candidate?
What is the focus of Pinetree Therapeutics' EGFR degrader candidate licensed to AstraZeneca (AZN)?
How was Pinetree Therapeutics' EGFR degrader candidate developed?